https://www.news-medical.net/news/20260417/Obesity-GLP-1s-and-metabolic-care.aspx
An interview with Professor Thomas Forst, Chief Medical Officer, hVIVO
Obesity research is a rapidly developing field, and few areas have advanced faster than incretin-based medicines such as GLP-1 receptor agonists.
No hay comentarios:
Publicar un comentario